The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Final results of a phase 2 study of tucatinib and trastuzumab for HER2-positive mCRC (MOUNTAINEER).
 
John H Strickler
Stock and Other Ownership Interests - Triumvira Immunologics, Inc
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Bayer; Beigene; Daiichi Sankyo/Astra Zeneca; GlaxoSmithKline; Janssen Oncology; Jazz Pharmaceuticals; Lilly; Merck; Natera (Inst); Pfizer; Roche/Genentech; Seagen; Taiho Oncology; Takeda
Research Funding - A*STAR (Inst); Abbvie (Inst); Amgen (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); BeiGene (Inst); Curegenix (Inst); Daiichi Sankyo/Lilly (Inst); Erasca, Inc (Inst); GlaxoSmithKline (Inst); Leap Therapeutics (Inst); Lilly (Inst); Roche/Genentech (Inst); Seagen (Inst)
Expert Testimony - Seagen
Travel, Accommodations, Expenses - Seagen
 
Andrea Cercek
Stock and Other Ownership Interests - Haystack Oncology
Consulting or Advisory Role - Bayer; Daiichi Sankyo/Astra Zeneca; G1 Therapeutics; GlaxoSmithKline; Incyte; Janssen; Merck; Seagen
Research Funding - GlaxoSmithKline; Seagen
Patents, Royalties, Other Intellectual Property - Hepatic arterial infusion with FUDR for colorectal liver metastases with DPD (Inst); Hepatic arterial infusion with FUDR for colorectal liver metastases with DPD (Inst); Neoadjuvant PD1 blockade in mismatch repair deficient solid tumors (Inst)
 
Salvatore Siena
Stock and Other Ownership Interests - Guardant Health; Myriad Genetics
Consulting or Advisory Role - Agenus; AstraZeneca; Bayer; Bristol-Myers Squibb; CheckmAb; Daiichi Sankyo; GlaxoSmithKline; Merck; MSD Oncology; Novartis; Pierre Fabre; Pierre Fabre; Seagen; T-One Therapeutics
Research Funding - MSD Oncology (Inst)
Patents, Royalties, Other Intellectual Property - Amgen
Travel, Accommodations, Expenses - Amgen; Bayer; Roche
 
Thierry Andre
Honoraria - AMGEN; Bristol-Myers Squibb; GlaxoSmithKline; Merck; Merck Serono; Merck Serono; Pierre Fabre; Roche/Genentech; Sanofi; Seagen; SERVIER; Ventana Medical Systems
Consulting or Advisory Role - Amgen; Aptitude Health; Astellas Pharma; AstraZeneca/MedImmune; Bristol-Myers Squibb; GamaMabs Pharma; Gilead Sciences; GlaxoSmithKline; Gritstone Bio; Kaleido Biosciences; MSD Oncology; Nordic Bioscience; Pierre Fabre; Seagen; SERVIER; Takeda/Lundbeck; Tesaro; Transgene
Travel, Accommodations, Expenses - MSD Oncology; MSD Oncology
(OPTIONAL) Uncompensated Relationships - Adjuvant Colon Cancer End Points (ACCENT) Collaborative Group; ARCAD Foundation; ARCAD Foundation; Gercor
 
Kimmie Ng
Honoraria - Seagen
Consulting or Advisory Role - Abbvie; Bayer; CytomX Therapeutics; GlaxoSmithKline; Jazz Pharmaceuticals; Pfizer; Revolution Medicines
Research Funding - Evergrande Group (Inst); Janssen (Inst); Pharmavite (Inst)
Expert Testimony - Crico
Other Relationship - jama
 
Eric Van Cutsem
Consulting or Advisory Role - Abbvie; Agenus; ALX Oncology; Amgen; Arcus Biosciences; Astellas Pharma; AstraZeneca; Bayer; BeiGene; BioNTech SE; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; Debiopharm Group; Eisai; ElmediX; GlaxoSmithKline; Hookipa Biotech; Incyte; Ipsen; Lilly; Merck KGaA; Merck Sharp & Dohme; Mirati Therapeutics; Nordic Group; Novartis; Pfizer; Pierre Fabre; Roche; Seagen; SERVIER; Simcere; Taiho Pharmaceutical; Takeda; TERUMO
 
Christina Wu
Honoraria - Cancer Treament Centers of America; Medscape
Consulting or Advisory Role - Daiichi Sankyo/Lilly; Exelixis; Natera; Natera; Nova Research Company; Pfizer; Seagen
Research Funding - HUTCHMED; Pfizer; Sirnaomics (Inst); Sumitomo Pharma (Inst)
 
Andrew Scott Paulson
Employment - Day One Biopharmaceuticals (I)
Stock and Other Ownership Interests - Actinium Pharmaceuticals
Honoraria - Array BioPharma; Cardinal Health; Curio Science
Consulting or Advisory Role - AADi; Advanced Accelerator Applications; Amgen; Array BioPharma; Astellas Pharma; AstraZeneca; Bayer; Bristol Myers Squibb; Eisai; EMD Serono; EMD Serono; Exelixis; Exelixis; Exelixis; Hutchison MediPharma; Incyte; Ipsen; Jazz Pharmaceuticals; Lilly; Mirati Therapeutics; Novartis; Pfizer; QED Therapeutics; Seagen; SERVIER; Stromatis Pharma; Takeda
Speakers' Bureau - Ideo Oncology
Research Funding - AstraZeneca (Inst); Bayer (Inst); BioNTech SE (Inst); bristol myers squibb (Inst); Buzzard Pharmaceuticals; Camurus (Inst); Camurus (Inst); Deciphera (Inst); Exelixis (Inst); G1 Therapeutics (Inst); Gilead Sciences (Inst); Gritstone Bio (Inst); Hutchison MediPharma (Inst); incyte (Inst); Innovative Cellular Therapeutics Co (Inst); Inspirna (Inst); Ipsen (Inst); ITM Oncologics (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Nucana (Inst); Regenxbio (Inst); Relay Therapeutics (Inst); Seagen (Inst); Sotio (Inst); Taiho Pharmaceutical (Inst); Tempus (Inst); TransThera Biosciences (Inst); Zentalis (Inst)
Travel, Accommodations, Expenses - AADi; Camurus; Mirati Therapeutics; Nucana; Pfizer
 
Joleen M. Hubbard
Employment - Allina Health Cancer Institute
Consulting or Advisory Role - Bayer (Inst); BeiGene (Inst); Incyte (Inst); Incyte (Inst); Merck; Seattle Genetics/Astellas; Taiho Oncology (Inst)
Research Funding - Bayer (Inst); G1 Therapeutics (Inst); Incyte (Inst); Merck (Inst); Pfizer (Inst); Pionyr (Inst); Seagen (Inst); Senhwa Biosciences (Inst); Taiho Pharmaceutical (Inst); Translational Research in Oncology (Inst); Treos Bio (Inst); Trovagene (Inst)
 
Andrew L. Coveler
Consulting or Advisory Role - Abbvie; Halozyme; Merrimack; Seagen
Research Funding - AbGenomics International (Inst); Actuate Therapeutics (Inst); Amgen (Inst); Amgen (Inst); AstraZeneca (Inst); Genentech (Inst); Gilead Sciences (Inst); Halozyme (Inst); Immunomedics (Inst); Lilly (Inst); Newlink Genetics (Inst); Nextrast (Inst); Novocure (Inst); Nucana (Inst); Onconova Therapeutics (Inst); Seagen (Inst); Surface Oncology (Inst); Taiho Pharmaceutical (Inst); XBiotech (Inst)
Travel, Accommodations, Expenses - Abbvie; Halozyme; Nucana
 
Christos Fountzilas
Research Funding - Amgen (Inst); Aravive (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bellicum Pharmaceuticals (Inst); Biomea Fusion (Inst); Bristol-Myers Squibb/Ono Pharmaceutical (Inst); Corcept Therapeutics (Inst); CrystalGenomics (Inst); Dragonfly Therapeutics (Inst); ERYTECH Pharma (Inst); Ipsen (Inst); Kadmon (Inst); Legend Biotech USA Inc (Inst); Lilly (Inst); Merck (Inst); Pfizer (Inst); Rafael Pharmaceuticals (Inst); Sanofi (Inst); Seagen (Inst); Taiho Oncology (Inst); TransThera Biosciences (Inst); Valar Labs (Inst)
Travel, Accommodations, Expenses - CG Pharmaceuticals
 
Adel Kardosh
Consulting or Advisory Role - Astellas Pharma; Astex Pharmaceuticals; AstraZeneca; Eisai; Genentech; Seagen
Research Funding - Natera
 
Pashtoon Murtaza Kasi
Leadership - Precision Biosensors
Stock and Other Ownership Interests - Elicio Therapeutics
Consulting or Advisory Role - Bayer; BostonGene; BostonGene; Daiichi Sankyo/Astra Zeneca; Delcath Systems; Eisai; Elicio Therapeutics; Exact Sciences; Foundation Medicine; Guardant Health; Illumina; Ipsen (Inst); Lilly; MSD Oncology; Natera; NeoGenomics Laboratories; QED Therapeutics; Regeneron; SAGA Diagnostics; Seagen; SERVIER; Taiho Oncology; Taiho Pharmaceutical (Inst); Tempus
Research Funding - Advanced Accelerator Applications (Inst); Boston Scientific (Inst); Tersera (Inst)
Travel, Accommodations, Expenses - AstraZeneca
 
Heinz-Josef Lenz
Honoraria - Bayer; Boehringer Ingelheim; Fulgent Genetics; G1 THerapeutics; Isofol Medical; Jazz Pharmaceuticals; Merck Serono; Oncocyte; Roche
Consulting or Advisory Role - 3T BioSciences; Bayer; BMS; Fulgent Genetics; GlaxoSmithKline; Merck Serono; Roche
Travel, Accommodations, Expenses - Bayer; BMS; Merck Serono
 
Kristen Keon Ciombor
Consulting or Advisory Role - Bayer; Exelixis; Incyte; Lilly; Merck; Personalis; Pfizer; Replimune; Seagen
Research Funding - Abbvie (Inst); Amgen (Inst); Array BioPharma (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); Genentech (Inst); Incyte (Inst); Incyte (Inst); MedImmune (Inst); Merck (Inst); Merck (Inst); Novartis (Inst); Nucana (Inst); Onyx (Inst); Pfizer (Inst); Pfizer/Calithera (Inst); Sanofi (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - Array BioPharma; Incyte
 
Elena Elez
Honoraria - Amgen; Array BioPharma; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Cure Teq AG; Janssen; Lilly; Medscape; Merck; Merck Serono; MSD; Novartis; Pfizer; Pierre Fabre; Repare Therapeutics; RIN Institute Inc.; Roche; Sanofi/Aventis; Seagan; SERVIER; Takeda
Consulting or Advisory Role - Amgen; Array BioPharma; Bayer; Bayer; Boehringer Ingelheim; Bristol Myers Squibb; Cure Teq AG; Janssen; Merck Serono; MSD; Novartis; Pfizer; Pierre Fabre; Repare Therapeutics Inc.; RIN Institute Inc.; Roche; Roche; Sanofi; Seagen; SERVIER; Takeda
Research Funding - Abbvie (Inst); Amgen (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); Bioncotech (Inst); Biontech Rna Pharmaceuticals GMBH (Inst); Biontech Small Molecules GMBH (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim Spain (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Daiichi Sankyo Inc. (Inst); Debiopharm Group (Inst); Genentech (Inst); Gercor (Inst); HalioDx (Inst); Hoffmann-La-Roche Ltd. (Inst); Hutchison MediPharma (Inst); Hutchison MediPharma (Inst); Iovance Biotherapeutics (Inst); Janssen Research & Development (Inst); Janssen-Cilag SA (Inst); MedImmune (Inst); Menarini (Inst); Menarini (Inst); Merck (Inst); Merck Sharp&Dohme de España SA (Inst); Merus NV (Inst); Mirati Therapeutics (Inst); Nouscom SRL. (Inst); Novartis (Inst); Novartis Farmacéutica SA (Inst); Pfizer (Inst); PharmaMar (Inst); Pierre Fabre (Inst); PledPharma (Inst); Redx Pharma (Inst); Roche (Inst); Sanofi (Inst); Scandion Oncology (Inst); Seagen (Inst); SERVIER (Inst); Sotio (Inst); Taiho Pharma USA (Inst); Taiho Pharmaceutical (Inst); WntResearch (Inst)
Travel, Accommodations, Expenses - Amgen; Array BioPharma; Bristol-Myers Squibb; Merck Serono; Roche; Sanofi; SERVIER
 
David L Bajor
Employment - University Hospitals Case Medical Center
Stock and Other Ownership Interests - Mirati Therapeutics
Consulting or Advisory Role - Guidepoint Global
Speakers' Bureau - Natera
Research Funding - Abbvie; Apexigen (Inst); Bristol-Myers Squibb/Celgene (Inst); Calithera Biosciences (Inst); GlaxoSmithKline (Inst); Rafael Pharmaceuticals (Inst); Seagen (Inst); Tesaro (Inst)
 
Mina Nayeri
Employment - Pfizer; Seagen
Stock and Other Ownership Interests - Pfizer; Seagen
Travel, Accommodations, Expenses - Pfizer; Seagen
 
Wentao Feng
Employment - Pfizer; Seagen
Stock and Other Ownership Interests - Pfizer; Seagen
Travel, Accommodations, Expenses - Pfizer; Seagen
 
Tanios S. Bekaii-Saab
Consulting or Advisory Role - Abbvie; Amgen (Inst); Arcus Biosciences (Inst); AstraZeneca; Bayer (Inst); BeiGene; Boehringer Ingelheim; Caladrius Biosciences; Caladrius Biosciences; Celularity; Daiichi Sankyo/UCB Japan; Deciphera; Eisai; Eisai; Exact Sciences; Foundation Medicine; Foundation Medicine; Illumina; Immuneering; Incyte (Inst); Ipsen (Inst); Janssen; Kanaph Therapeutics; Lilly (Inst); Natera; Pfizer (Inst); Roche/Genentech (Inst); Seagen (Inst); SOBI; Stemline Therapeutics; Treos Bio; Zai Lab
Patents, Royalties, Other Intellectual Property - Patent WO/2018/183488; Patent WO/2019/055687
Other Relationship - 1Globe Health Institute; AstraZeneca; Exelixis; FibroGen; Imugene; Lilly; Merck (Inst); Pancreatic Cancer Action Network; Replimune; Sun Biopharma; Suzhou Kintor Pharmaceuticals; UpToDate; Xilis